You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSorafenib
Accession NumberDB00398  (APRD01304, DB07438)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionSorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.
Structure
Thumb
Synonyms
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
Sorafenibum
External Identifiers
  • BAY 43-9006
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nexavartablet, film coated200 mg/1oralBayer Health Care Pharmaceuticals Inc.2005-12-20Not applicableUs
Nexavartablet200 mgoralBayer Inc2006-07-31Not applicableCanada
NexavarFilm-coated tablet200 mgOral useBayer Pharma Ag2006-07-19Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Sorafenib Tosylate
Thumb
  • InChI Key: IVDHYUQIDRJSTI-UHFFFAOYSA-N
  • Monoisotopic Mass: 636.105717532
  • Average Mass: 637.027
DBSALT000165
Categories
UNII9ZOQ3TZI87
CAS number284461-73-0
WeightAverage: 464.825
Monoisotopic: 464.08630272
Chemical FormulaC21H16ClF3N4O3
InChI KeyInChIKey=MLDQJTXFUGDVEO-UHFFFAOYSA-N
InChI
InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
IUPAC Name
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
SMILES
CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassEthers
Sub ClassDiarylethers
Direct ParentDiarylethers
Alternative Parents
Substituents
  • Diaryl ether
  • N-phenylurea
  • Pyridine carboxylic acid or derivatives
  • Pyridinecarboxamide
  • Halobenzene
  • Chlorobenzene
  • Benzenoid
  • Pyridine
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Urea
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationSorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
PharmacodynamicsNo large changes in QTc interval were observed. After one 28-day treatment cycle, the largest mean QTc interval change of 8.5 ms (upper bound of two-sided 90% confidence interval, 13.3 ms) was observed at 6 hours post-dose on day 1 of cycle 2.
Mechanism of actionSorafenib interacts with multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß). Several of these kinases are thought to be involved in angiogenesis, thus sorafenib reduces blood flow to the tumor. Sorafenib is unique in targeting the Raf/Mek/Erk pathway. By inhibiting these kinases, genetic transcription involving cell proliferation and angiogenesis is inhibited.
Related Articles
AbsorptionThe mean relative bioavailability is 38-49% for the tablet form, when compared to an oral solution. Sorafenib reached peak plasma levels in 3 hours following oral administration. With a high-fat meal, bioavailability is reduced by 29% compared to administration in the fasted state.
Volume of distributionNot Available
Protein binding99.5% bound to plasma proteins.
Metabolism

Sorafenib is metabolized primarily in the liver, undergoing oxidative metabolism, mediated by CYP3A4, as well as glucuronidation mediated by UGT1A9. Sorafenib accounts for approximately 70-85% of the circulating analytes in plasma at steady- state. Eight metabolites of sorafenib have been identified, of which five have been detected in plasma. The main circulating metabolite of sorafenib in plasma, the pyridine N-oxide, shows in vitro potency similar to that of sorafenib. This metabolite comprises approximately 9-16% of circulating analytes at steady-state.

SubstrateEnzymesProduct
Sorafenib
Pyridine N-oxideDetails
Sorafenib
Not Available
Pyridine N-oxide glucuronideDetails
Sorafenib
Sorafenib beta-D-GlucuronideDetails
Route of eliminationFollowing oral administration of a 100 mg dose of a solution formulation of sorafenib, 96% of the dose was recovered within 14 days, with 77% of the dose excreted in feces, and 19% of the dose excreted in urine as glucuronidated metabolites.
Half life25-48 hours
ClearanceNot Available
ToxicityThe highest dose of sorafenib studied clinically is 800 mg twice daily. The adverse reactions observed at this dose were primarily diarrhea and dermatologic events. No information is available on symptoms of acute overdose in animals because of the saturation of absorption in oral acute toxicity studies conducted in animals.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Sorafenib Metabolism PathwayDrug metabolismSMP00648
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9649
Blood Brain Barrier+0.851
Caco-2 permeable-0.5138
P-glycoprotein substrateNon-substrate0.5086
P-glycoprotein inhibitor INon-inhibitor0.7141
P-glycoprotein inhibitor IINon-inhibitor0.9359
Renal organic cation transporterNon-inhibitor0.8938
CYP450 2C9 substrateNon-substrate0.6569
CYP450 2D6 substrateNon-substrate0.8212
CYP450 3A4 substrateNon-substrate0.5341
CYP450 1A2 substrateInhibitor0.6168
CYP450 2C9 inhibitorNon-inhibitor0.6171
CYP450 2D6 inhibitorNon-inhibitor0.9145
CYP450 2C19 inhibitorInhibitor0.637
CYP450 3A4 inhibitorNon-inhibitor0.7339
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6629
Ames testNon AMES toxic0.8143
CarcinogenicityNon-carcinogens0.8684
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7885 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9488
hERG inhibition (predictor II)Non-inhibitor0.6415
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Bayer healthcare pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Film-coated tabletOral use200 mg
Tabletoral200 mg
Tablet, film coatedoral200 mg/1
Prices
Unit descriptionCostUnit
Nexavar 200 mg tablet66.61USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2315715 No2010-06-222018-12-22Canada
CA2359510 No2007-02-132020-01-12Canada
US7235576 No2000-01-122020-01-12Us
US7351834 No2000-01-122020-01-12Us
US7897623 No2000-01-122020-01-12Us
US8124630 No2000-01-122020-01-12Us
US8618141 No2003-02-112023-02-11Us
US8841330 No2000-01-122020-01-12Us
US8877933 No2007-12-242027-12-24Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsolubleFDA label
logP3.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00171 mg/mLALOGPS
logP4.12ALOGPS
logP4.34ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)11.55ChemAxon
pKa (Strongest Basic)2.03ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area92.35 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity114.52 m3·mol-1ChemAxon
Polarizability41.11 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Ales Gavenda, Alexandr Jegorov, Pierluigi Rossetto, Peter Lindsay MacDonald, Augusto Canavesi, “POLYMORPHS OF SORAFENIB TOSYLATE AND SORAFENIB HEMI-TOSYLATE, AND PROCESSES FOR PREPARATION THEREOF.” U.S. Patent US20090192200, issued July 30, 2009.

US20090192200
General ReferencesNot Available
External Links
ATC CodesL01XE05
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (310 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Sorafenib can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Sorafenib.
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Sorafenib.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Sorafenib.
AcetaminophenThe serum concentration of Sorafenib can be increased when it is combined with Acetaminophen.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Sorafenib.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Sorafenib.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Sorafenib.
AlbendazoleThe serum concentration of Sorafenib can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Sorafenib can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Sorafenib.
AlectinibThe serum concentration of Sorafenib can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Sorafenib can be increased when it is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Sorafenib.
AlosetronThe metabolism of Alosetron can be decreased when combined with Sorafenib.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Sorafenib.
AmantadineThe serum concentration of Sorafenib can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Sorafenib.
Aminohippuric acidThe serum concentration of Sorafenib can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Sorafenib.
AmiodaroneThe serum concentration of Sorafenib can be increased when it is combined with Amiodarone.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Sorafenib.
AmitriptylineThe serum concentration of Sorafenib can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Sorafenib can be increased when it is combined with Amlodipine.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Sorafenib.
AmprenavirThe serum concentration of Sorafenib can be decreased when it is combined with Amprenavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Sorafenib.
AmsacrineThe serum concentration of Sorafenib can be increased when it is combined with Amsacrine.
AnagrelideSorafenib may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Sorafenib.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Sorafenib.
AprepitantThe serum concentration of Sorafenib can be increased when it is combined with Aprepitant.
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Sorafenib.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Sorafenib.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Sorafenib.
ArtemetherThe metabolism of Artemether can be decreased when combined with Sorafenib.
AsenapineSorafenib may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe serum concentration of Sorafenib can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Sorafenib can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Sorafenib can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Sorafenib can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Sorafenib can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Sorafenib.
AzelastineThe serum concentration of Sorafenib can be increased when it is combined with Azelastine.
AzelastineThe metabolism of Azelastine can be decreased when combined with Sorafenib.
AzithromycinSorafenib may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe serum concentration of Sorafenib can be increased when it is combined with Azithromycin.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Sorafenib.
BedaquilineSorafenib may increase the QTc-prolonging activities of Bedaquiline.
BenzocaineThe serum concentration of Sorafenib can be increased when it is combined with Benzocaine.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Sorafenib.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Sorafenib.
BepridilThe serum concentration of Sorafenib can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Sorafenib.
BevacizumabThe risk or severity of adverse effects can be increased when Bevacizumab is combined with Sorafenib.
BexaroteneThe serum concentration of Sorafenib can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Sorafenib.
BiperidenThe serum concentration of Sorafenib can be increased when it is combined with Biperiden.
BoceprevirThe serum concentration of Sorafenib can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Sorafenib can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Sorafenib can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Sorafenib.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Sorafenib.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sorafenib.
BromocriptineThe serum concentration of Sorafenib can be increased when it is combined with Bromocriptine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Sorafenib.
BuprenorphineThe serum concentration of Sorafenib can be increased when it is combined with Buprenorphine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Sorafenib.
BupropionThe serum concentration of Bupropion can be increased when it is combined with Sorafenib.
BuspironeThe serum concentration of Sorafenib can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Sorafenib.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Sorafenib.
CaffeineThe serum concentration of Sorafenib can be increased when it is combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Sorafenib.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Sorafenib.
CandesartanThe serum concentration of Sorafenib can be increased when it is combined with Candesartan.
CandesartanThe metabolism of Candesartan can be decreased when combined with Sorafenib.
CaptoprilThe serum concentration of Sorafenib can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Sorafenib can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Sorafenib.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Sorafenib.
CarboplatinThe risk or severity of adverse effects can be increased when Sorafenib is combined with Carboplatin.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Sorafenib.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Sorafenib.
CaspofunginThe serum concentration of Sorafenib can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Sorafenib.
CeritinibThe serum concentration of Sorafenib can be increased when it is combined with Ceritinib.
CeritinibSorafenib may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Sorafenib.
ChloroquineSorafenib may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe serum concentration of Sorafenib can be increased when it is combined with Chloroquine.
ChlorpromazineSorafenib may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe serum concentration of Sorafenib can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Sorafenib can be increased when it is combined with Chlorpropamide.
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Sorafenib.
ChlorprothixeneThe serum concentration of Sorafenib can be increased when it is combined with Chlorprothixene.
CholesterolThe serum concentration of Sorafenib can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Sorafenib can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Sorafenib can be increased when it is combined with Cilazapril.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Sorafenib.
CimetidineThe serum concentration of Sorafenib can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Sorafenib.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Sorafenib.
CiprofloxacinSorafenib may increase the QTc-prolonging activities of Ciprofloxacin.
CiprofloxacinThe serum concentration of Sorafenib can be increased when it is combined with Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be decreased when combined with Sorafenib.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Sorafenib.
CitalopramThe serum concentration of Sorafenib can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Sorafenib can be increased when it is combined with Clarithromycin.
ClarithromycinSorafenib may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe metabolism of Sorafenib can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Sorafenib.
ClofazimineThe serum concentration of Sorafenib can be increased when it is combined with Clofazimine.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Sorafenib.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Sorafenib.
ClomipramineThe serum concentration of Sorafenib can be increased when it is combined with Clomipramine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Sorafenib.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Sorafenib.
ClopidogrelThe metabolism of Sorafenib can be decreased when combined with Clopidogrel.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Sorafenib.
ClotrimazoleThe metabolism of Sorafenib can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Sorafenib is combined with Clozapine.
CobicistatThe serum concentration of Sorafenib can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Sorafenib.
ColchicineThe serum concentration of Sorafenib can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Sorafenib can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Sorafenib can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Sorafenib.
CrizotinibSorafenib may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Sorafenib can be decreased when combined with Crizotinib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Sorafenib.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Sorafenib.
CyclosporineThe metabolism of Sorafenib can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Sorafenib.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Sorafenib.
DabrafenibThe serum concentration of Sorafenib can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Sorafenib.
DacarbazineThe serum concentration of Dacarbazine can be decreased when it is combined with Sorafenib.
DaclatasvirThe serum concentration of Sorafenib can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Sorafenib can be increased when it is combined with Dactinomycin.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Sorafenib.
DapsoneThe metabolism of Dapsone can be decreased when combined with Sorafenib.
DarunavirThe serum concentration of Sorafenib can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Sorafenib can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Sorafenib can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Sorafenib.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Sorafenib.
DeferasiroxThe serum concentration of Sorafenib can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Sorafenib can be decreased when combined with Delavirdine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Sorafenib.
DesipramineThe serum concentration of Sorafenib can be increased when it is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Sorafenib.
DesloratadineThe serum concentration of Sorafenib can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Sorafenib can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Sorafenib.
DextromethorphanThe serum concentration of Sorafenib can be increased when it is combined with Dextromethorphan.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Sorafenib.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Sorafenib.
DiclofenacThe serum concentration of Sorafenib can be increased when it is combined with Diclofenac.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Sorafenib.
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Sorafenib.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Sorafenib.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Sorafenib.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Sorafenib.
DigoxinDigoxin may decrease the cardiotoxic activities of Sorafenib.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Sorafenib.
DihydroergotamineThe metabolism of Sorafenib can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Sorafenib.
DiltiazemThe metabolism of Sorafenib can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Sorafenib.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Sorafenib.
DipyridamoleThe serum concentration of Sorafenib can be increased when it is combined with Dipyridamole.
DisopyramideSorafenib may increase the QTc-prolonging activities of Disopyramide.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Sorafenib.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sorafenib.
DofetilideSorafenib may increase the QTc-prolonging activities of Dofetilide.
DolasetronSorafenib may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Sorafenib.
DonepezilThe metabolism of Donepezil can be decreased when combined with Sorafenib.
DopamineThe metabolism of Dopamine can be decreased when combined with Sorafenib.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Sorafenib.
DoxazosinThe serum concentration of Sorafenib can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Sorafenib can be increased when it is combined with Doxepin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Sorafenib.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Sorafenib.
DoxorubicinThe serum concentration of Sorafenib can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Sorafenib can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Sorafenib.
DronedaroneThe metabolism of Sorafenib can be decreased when combined with Dronedarone.
DronedaroneSorafenib may increase the QTc-prolonging activities of Dronedarone.
DroperidolSorafenib may increase the QTc-prolonging activities of Droperidol.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Sorafenib.
EfavirenzThe serum concentration of Sorafenib can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Sorafenib.
ElbasvirThe serum concentration of Sorafenib can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Sorafenib.
EliglustatSorafenib may increase the QTc-prolonging activities of Eliglustat.
EltrombopagThe serum concentration of Sorafenib can be increased when it is combined with Eltrombopag.
EnalaprilThe serum concentration of Sorafenib can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Sorafenib can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Sorafenib.
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Sorafenib.
ErgonovineThe serum concentration of Sorafenib can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Sorafenib can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Sorafenib.
ErythromycinSorafenib may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Sorafenib can be decreased when combined with Erythromycin.
EscitalopramSorafenib may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Sorafenib can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Sorafenib.
EstramustineThe serum concentration of Sorafenib can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Sorafenib can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Sorafenib.
EstroneThe serum concentration of Sorafenib can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Sorafenib.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Sorafenib.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Sorafenib.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Sorafenib.
EtodolacThe metabolism of Etodolac can be decreased when combined with Sorafenib.
EtoposideThe serum concentration of Sorafenib can be increased when it is combined with Etoposide.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Sorafenib.
EtravirineThe serum concentration of Sorafenib can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Sorafenib.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Sorafenib.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Sorafenib.
FelodipineThe serum concentration of Sorafenib can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Sorafenib can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sorafenib.
FexofenadineThe serum concentration of Sorafenib can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Sorafenib.
FingolimodSorafenib may increase the immunosuppressive activities of Fingolimod.
FlecainideSorafenib may increase the QTc-prolonging activities of Flecainide.
FluconazoleThe metabolism of Sorafenib can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Sorafenib.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Sorafenib.
FluorouracilThe serum concentration of Fluorouracil can be decreased when it is combined with Sorafenib.
FluoxetineThe serum concentration of Sorafenib can be increased when it is combined with Fluoxetine.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Sorafenib.
FlupentixolThe serum concentration of Sorafenib can be increased when it is combined with Flupentixol.
FlupentixolSorafenib may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe serum concentration of Sorafenib can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Sorafenib can be increased when it is combined with Flurazepam.
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Sorafenib.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Sorafenib.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Sorafenib.
FluvoxamineThe metabolism of Sorafenib can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Sorafenib.
FosamprenavirThe metabolism of Sorafenib can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Sorafenib can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Sorafenib can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Sorafenib.
Fusidic AcidThe serum concentration of Sorafenib can be increased when it is combined with Fusidic Acid.
Gadobenic acidSorafenib may increase the QTc-prolonging activities of Gadobenic acid.
GavestinelThe metabolism of Gavestinel can be decreased when combined with Sorafenib.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Sorafenib.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Sorafenib.
GemfibrozilThe metabolism of Sorafenib can be decreased when combined with Gemfibrozil.
GemifloxacinSorafenib may increase the QTc-prolonging activities of Gemifloxacin.
GenisteinThe serum concentration of Sorafenib can be increased when it is combined with Genistein.
GliclazideThe metabolism of Gliclazide can be decreased when combined with Sorafenib.
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Sorafenib.
GlipizideThe metabolism of Glipizide can be decreased when combined with Sorafenib.
GlyburideThe serum concentration of Sorafenib can be increased when it is combined with Glyburide.
GlyburideThe metabolism of Glyburide can be decreased when combined with Sorafenib.
GlycerolThe serum concentration of Sorafenib can be increased when it is combined with Glycerol.
GoserelinSorafenib may increase the QTc-prolonging activities of Goserelin.
Gramicidin DThe serum concentration of Sorafenib can be increased when it is combined with Gramicidin D.
GranisetronSorafenib may increase the QTc-prolonging activities of Granisetron.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Sorafenib.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Sorafenib.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Sorafenib.
HaloperidolSorafenib may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe serum concentration of Sorafenib can be increased when it is combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Sorafenib.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Sorafenib.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Sorafenib.
HydrocortisoneThe serum concentration of Sorafenib can be increased when it is combined with Hydrocortisone.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Sorafenib.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Sorafenib.
IbutilideSorafenib may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Sorafenib.
IdelalisibThe serum concentration of Sorafenib can be increased when it is combined with Idelalisib.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Sorafenib.
IloperidoneSorafenib may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe metabolism of Sorafenib can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Sorafenib.
ImipramineThe serum concentration of Sorafenib can be increased when it is combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Sorafenib.
IndinavirThe serum concentration of Sorafenib can be increased when it is combined with Indinavir.
indisulamThe metabolism of indisulam can be decreased when combined with Sorafenib.
IndomethacinThe serum concentration of Sorafenib can be increased when it is combined with Indomethacin.
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Sorafenib.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Sorafenib.
IsavuconazoniumThe metabolism of Sorafenib can be decreased when combined with Isavuconazonium.
IsofluraneThe metabolism of Isoflurane can be decreased when combined with Sorafenib.
IsradipineThe metabolism of Sorafenib can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Sorafenib can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Sorafenib can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Sorafenib can be increased when it is combined with Ivermectin.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Sorafenib.
KetamineThe serum concentration of Sorafenib can be increased when it is combined with Ketamine.
KetamineThe metabolism of Ketamine can be decreased when combined with Sorafenib.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Sorafenib.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Sorafenib.
KetoconazoleThe serum concentration of Sorafenib can be increased when it is combined with Ketoconazole.
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Sorafenib.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Sorafenib.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Sorafenib.
LansoprazoleThe serum concentration of Sorafenib can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Sorafenib can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Sorafenib.
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Sorafenib.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Sorafenib.
LenvatinibSorafenib may increase the QTc-prolonging activities of Lenvatinib.
LesinuradThe metabolism of Lesinurad can be decreased when combined with Sorafenib.
LeuprolideSorafenib may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Sorafenib.
LevofloxacinSorafenib may increase the QTc-prolonging activities of Levofloxacin.
LevofloxacinThe serum concentration of Sorafenib can be increased when it is combined with Levofloxacin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Sorafenib.
LevothyroxineThe serum concentration of Sorafenib can be decreased when it is combined with Levothyroxine.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Sorafenib.
LidocaineThe serum concentration of Sorafenib can be increased when it is combined with Lidocaine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Sorafenib.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Sorafenib.
LiothyronineThe serum concentration of Sorafenib can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Sorafenib can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Sorafenib can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Sorafenib can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Sorafenib can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Sorafenib can be increased when it is combined with Lopinavir.
LopinavirSorafenib may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe serum concentration of Sorafenib can be increased when it is combined with Loratadine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Sorafenib.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Sorafenib.
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Sorafenib.
LosartanThe serum concentration of Sorafenib can be increased when it is combined with Losartan.
LovastatinThe metabolism of Sorafenib can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Sorafenib can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Sorafenib can be decreased when it is combined with Lumacaftor.
LumefantrineSorafenib may increase the QTc-prolonging activities of Lumefantrine.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Sorafenib.
MalathionThe metabolism of Malathion can be decreased when combined with Sorafenib.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Sorafenib.
MaprotilineThe serum concentration of Sorafenib can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Sorafenib can be increased when it is combined with Mebendazole.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Sorafenib.
MefloquineThe serum concentration of Sorafenib can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Sorafenib can be increased when it is combined with Megestrol acetate.
MelatoninThe metabolism of Melatonin can be decreased when combined with Sorafenib.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Sorafenib.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Sorafenib.
MeprobamateThe serum concentration of Sorafenib can be increased when it is combined with Meprobamate.
MestranolThe metabolism of Mestranol can be decreased when combined with Sorafenib.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Sorafenib.
MethadoneSorafenib may increase the QTc-prolonging activities of Methadone.
MethadoneThe serum concentration of Sorafenib can be increased when it is combined with Methadone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Sorafenib.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Sorafenib.
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Sorafenib.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Sorafenib.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Sorafenib.
MetoprololThe serum concentration of Sorafenib can be increased when it is combined with Metoprolol.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Sorafenib.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Sorafenib.
MianserinThe metabolism of Mianserin can be decreased when combined with Sorafenib.
MibefradilThe serum concentration of Sorafenib can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Sorafenib can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Sorafenib can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Sorafenib.
MifepristoneThe metabolism of Sorafenib can be decreased when combined with Mifepristone.
MifepristoneSorafenib may increase the QTc-prolonging activities of Mifepristone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Sorafenib.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Sorafenib.
MitomycinThe serum concentration of Sorafenib can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Sorafenib can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Sorafenib can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Sorafenib.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Sorafenib.
ModafinilThe serum concentration of Sorafenib can be decreased when it is combined with Modafinil.
MontelukastThe metabolism of Montelukast can be decreased when combined with Sorafenib.
MorphineThe serum concentration of Sorafenib can be increased when it is combined with Morphine.
MoxifloxacinSorafenib may increase the QTc-prolonging activities of Moxifloxacin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sorafenib.
NadololThe serum concentration of Nadolol can be increased when it is combined with Sorafenib.
NafcillinThe serum concentration of Sorafenib can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Sorafenib.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Sorafenib.
NaltrexoneThe serum concentration of Sorafenib can be increased when it is combined with Naltrexone.
NaproxenThe metabolism of Naproxen can be decreased when combined with Sorafenib.
NaringeninThe serum concentration of Sorafenib can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Sorafenib is combined with Natalizumab.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Sorafenib.
NefazodoneThe serum concentration of Sorafenib can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Sorafenib can be increased when it is combined with Nelfinavir.
NeomycinThe serum concentration of Sorafenib can be decreased when it is combined with Neomycin.
NeostigmineThe serum concentration of Sorafenib can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Sorafenib can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Sorafenib.
NevirapineThe serum concentration of Sorafenib can be decreased when it is combined with Nevirapine.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Sorafenib.
NicardipineThe serum concentration of Sorafenib can be increased when it is combined with Nicardipine.
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Sorafenib.
NicotineThe metabolism of Nicotine can be decreased when combined with Sorafenib.
NifedipineThe serum concentration of Sorafenib can be decreased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Sorafenib.
NilotinibThe metabolism of Sorafenib can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Sorafenib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Sorafenib.
NisoldipineThe serum concentration of Sorafenib can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Sorafenib can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Sorafenib can be increased when it is combined with Nitrendipine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Sorafenib.
NorethisteroneThe serum concentration of Sorafenib can be decreased when it is combined with Norethisterone.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Sorafenib.
OfloxacinSorafenib may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Sorafenib.
OlaparibThe metabolism of Sorafenib can be decreased when combined with Olaparib.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Sorafenib.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Sorafenib.
OmeprazoleThe serum concentration of Sorafenib can be increased when it is combined with Omeprazole.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Sorafenib.
OndansetronSorafenib may increase the QTc-prolonging activities of Ondansetron.
OsimertinibThe serum concentration of Sorafenib can be increased when it is combined with Osimertinib.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Sorafenib.
OuabainOuabain may decrease the cardiotoxic activities of Sorafenib.
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Sorafenib.
P-NitrophenolThe serum concentration of Sorafenib can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe risk or severity of adverse effects can be increased when Sorafenib is combined with Paclitaxel.
PaclitaxelThe serum concentration of Sorafenib can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Sorafenib can be increased when it is combined with Palbociclib.
PaliperidoneSorafenib may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Sorafenib can be increased when it is combined with Palmitic Acid.
PanobinostatSorafenib may increase the QTc-prolonging activities of Panobinostat.
PantoprazoleThe serum concentration of Sorafenib can be increased when it is combined with Pantoprazole.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Sorafenib.
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Sorafenib.
ParoxetineThe serum concentration of Sorafenib can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Sorafenib.
PentamidineSorafenib may increase the QTc-prolonging activities of Pentamidine.
PentobarbitalThe serum concentration of Sorafenib can be decreased when it is combined with Pentobarbital.
PerflutrenSorafenib may increase the QTc-prolonging activities of Perflutren.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Sorafenib.
PerindoprilThe serum concentration of Sorafenib can be increased when it is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be decreased when combined with Sorafenib.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Sorafenib.
PethidineThe metabolism of Pethidine can be decreased when combined with Sorafenib.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Sorafenib.
PhenobarbitalThe serum concentration of Sorafenib can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Sorafenib.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Sorafenib.
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Sorafenib.
PhenytoinThe serum concentration of Sorafenib can be decreased when it is combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Sorafenib.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sorafenib.
PimozideThe serum concentration of Sorafenib can be increased when it is combined with Pimozide.
PimozideSorafenib may increase the QTc-prolonging activities of Pimozide.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Sorafenib.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Sorafenib.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Sorafenib.
Platelet Activating FactorThe serum concentration of Sorafenib can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Sorafenib.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Sorafenib.
PosaconazoleThe serum concentration of Sorafenib can be increased when it is combined with Posaconazole.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Sorafenib.
PravastatinThe serum concentration of Sorafenib can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Sorafenib can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Sorafenib.
PrednisoneThe serum concentration of Sorafenib can be increased when it is combined with Prednisone.
PrimaquineSorafenib may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe serum concentration of Sorafenib can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Sorafenib can be increased when it is combined with Probenecid.
ProcainamideSorafenib may increase the QTc-prolonging activities of Procainamide.
ProgesteroneThe serum concentration of Sorafenib can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Sorafenib.
ProguanilThe metabolism of Proguanil can be decreased when combined with Sorafenib.
PromazineSorafenib may increase the QTc-prolonging activities of Promazine.
PromethazineThe serum concentration of Sorafenib can be increased when it is combined with Promethazine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Sorafenib.
PropacetamolSorafenib may increase the hepatotoxic activities of Propacetamol.
PropafenoneSorafenib may increase the QTc-prolonging activities of Propafenone.
PropafenoneThe serum concentration of Sorafenib can be increased when it is combined with Propafenone.
PropofolThe metabolism of Propofol can be decreased when combined with Sorafenib.
PropranololThe serum concentration of Sorafenib can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Sorafenib can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Sorafenib.
QuazepamThe serum concentration of Sorafenib can be increased when it is combined with Quazepam.
QuazepamThe metabolism of Quazepam can be decreased when combined with Sorafenib.
QuercetinThe serum concentration of Sorafenib can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Sorafenib.
QuinacrineThe serum concentration of Sorafenib can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Sorafenib can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Sorafenib can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Sorafenib can be decreased when combined with Rabeprazole.
Rabies vaccineThe risk or severity of adverse effects can be increased when Sorafenib is combined with Rabies vaccine.
RanitidineThe serum concentration of Sorafenib can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Sorafenib.
ReboxetineThe serum concentration of Sorafenib can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Sorafenib can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Sorafenib can be decreased when it is combined with Reserpine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Sorafenib.
RifabutinThe serum concentration of Sorafenib can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Sorafenib can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Sorafenib.
RifapentineThe serum concentration of Sorafenib can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Sorafenib.
RilpivirineThe serum concentration of Sorafenib can be increased when it is combined with Rilpivirine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Sorafenib.
RitonavirThe serum concentration of Sorafenib can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Sorafenib.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Sorafenib.
RoflumilastRoflumilast may increase the immunosuppressive activities of Sorafenib.
RolapitantThe serum concentration of Sorafenib can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Sorafenib.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Sorafenib.
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Sorafenib.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Sorafenib.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Sorafenib.
SaquinavirThe serum concentration of Sorafenib can be increased when it is combined with Saquinavir.
SaquinavirSorafenib may increase the QTc-prolonging activities of Saquinavir.
ScopolamineThe serum concentration of Sorafenib can be increased when it is combined with Scopolamine.
SecobarbitalThe metabolism of Sorafenib can be increased when combined with Secobarbital.
SelegilineThe serum concentration of Sorafenib can be increased when it is combined with Selegiline.
SelegilineThe metabolism of Selegiline can be decreased when combined with Sorafenib.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Sorafenib.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Sorafenib.
SertralineThe serum concentration of Sorafenib can be increased when it is combined with Sertraline.
SertralineThe metabolism of Sertraline can be decreased when combined with Sorafenib.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Sorafenib.
SildenafilThe metabolism of Sorafenib can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Sorafenib.
SiltuximabThe serum concentration of Sorafenib can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Sorafenib can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Sorafenib can be increased when it is combined with Simvastatin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Sorafenib.
SirolimusThe serum concentration of Sorafenib can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Sorafenib.
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Sorafenib.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Sorafenib.
SotalolSorafenib may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Sorafenib.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Sorafenib can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Sorafenib can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Sorafenib can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Sorafenib can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Sorafenib can be decreased when it is combined with Streptozocin.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Sorafenib.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Sorafenib.
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Sorafenib.
SulfinpyrazoneThe serum concentration of Sorafenib can be increased when it is combined with Sulfinpyrazone.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Sorafenib.
SulfisoxazoleSorafenib may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Sorafenib can be decreased when combined with Sulfisoxazole.
SumatriptanThe serum concentration of Sorafenib can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Sorafenib can be increased when it is combined with Sunitinib.
SuprofenThe metabolism of Suprofen can be decreased when combined with Sorafenib.
TacrineThe serum concentration of Sorafenib can be increased when it is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Sorafenib.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Sorafenib.
TamoxifenThe serum concentration of Sorafenib can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Sorafenib.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Sorafenib.
Taurocholic AcidThe serum concentration of Sorafenib can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Sorafenib.
TelaprevirThe serum concentration of Sorafenib can be increased when it is combined with Telaprevir.
TelavancinSorafenib may increase the QTc-prolonging activities of Telavancin.
TelithromycinThe serum concentration of Sorafenib can be increased when it is combined with Telithromycin.
TelithromycinSorafenib may increase the QTc-prolonging activities of Telithromycin.
TelmisartanThe serum concentration of Sorafenib can be increased when it is combined with Telmisartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Sorafenib.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Sorafenib.
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Sorafenib.
TerazosinThe serum concentration of Sorafenib can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Sorafenib.
TerfenadineThe serum concentration of Sorafenib can be increased when it is combined with Terfenadine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Sorafenib.
TeriflunomideThe serum concentration of Sorafenib can be increased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Sorafenib can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Sorafenib can be increased when it is combined with Testosterone.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Sorafenib.
TetrabenazineSorafenib may increase the QTc-prolonging activities of Tetrabenazine.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Sorafenib.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Sorafenib.
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Sorafenib.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Sorafenib.
ThiotepaThe metabolism of Sorafenib can be decreased when combined with Thiotepa.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Sorafenib.
TiclopidineThe metabolism of Sorafenib can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Sorafenib.
TocilizumabThe serum concentration of Sorafenib can be decreased when it is combined with Tocilizumab.
TofacitinibSorafenib may increase the immunosuppressive activities of Tofacitinib.
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Sorafenib.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Sorafenib.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Sorafenib.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Sorafenib.
TorasemideThe metabolism of Torasemide can be decreased when combined with Sorafenib.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Sorafenib.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Sorafenib.
TramadolThe metabolism of Tramadol can be decreased when combined with Sorafenib.
TrastuzumabTrastuzumab may increase the neutropenic activities of Sorafenib.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Sorafenib.
TrazodoneThe serum concentration of Sorafenib can be decreased when it is combined with Trazodone.
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Sorafenib.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Sorafenib.
TrifluoperazineThe serum concentration of Sorafenib can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Sorafenib can be increased when it is combined with Triflupromazine.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Sorafenib.
TrimethoprimThe serum concentration of Sorafenib can be decreased when it is combined with Trimethoprim.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Sorafenib.
TrimipramineThe serum concentration of Sorafenib can be increased when it is combined with Trimipramine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Sorafenib.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Sorafenib.
TroleandomycinThe serum concentration of Sorafenib can be increased when it is combined with Troleandomycin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Sorafenib.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Sorafenib.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Sorafenib.
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Sorafenib.
ValsartanThe metabolism of Valsartan can be decreased when combined with Sorafenib.
VandetanibSorafenib may increase the QTc-prolonging activities of Vandetanib.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Sorafenib.
VemurafenibSorafenib may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Sorafenib can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Sorafenib.
VerapamilThe metabolism of Sorafenib can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Sorafenib.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Sorafenib.
VinblastineThe serum concentration of Sorafenib can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Sorafenib.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Sorafenib.
VincristineThe serum concentration of Sorafenib can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Sorafenib can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Sorafenib.
VoriconazoleThe serum concentration of Sorafenib can be increased when it is combined with Voriconazole.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Sorafenib.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Sorafenib.
WarfarinThe metabolism of Warfarin can be decreased when combined with Sorafenib.
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Sorafenib.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Sorafenib.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Sorafenib.
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Sorafenib.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Sorafenib.
ZileutonThe metabolism of Zileuton can be decreased when combined with Sorafenib.
ZimelidineThe serum concentration of Sorafenib can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Sorafenib can be decreased when combined with Ziprasidone.
ZiprasidoneSorafenib may increase the QTc-prolonging activities of Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Sorafenib.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Sorafenib.
ZuclopenthixolSorafenib may increase the QTc-prolonging activities of Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Protein serine/threonine kinase activity
Specific Function:
Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Phosphorylates MAP2K1, and thereby contributes to the MAP kinase signal transduction pathway.
Gene Name:
BRAF
Uniprot ID:
P15056
Molecular Weight:
84436.135 Da
References
  1. Flaherty KT: Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2366s-2370s. [PubMed:16609060 ]
  2. Haluska FG, Ibrahim N: Therapeutic targets in melanoma: map kinase pathway. Curr Oncol Rep. 2006 Sep;8(5):400-5. [PubMed:16901402 ]
  3. Kim S, Yazici YD, Calzada G, Wang ZY, Younes MN, Jasser SA, El-Naggar AK, Myers JN: Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther. 2007 Jun;6(6):1785-92. [PubMed:17575107 ]
  4. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ: Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006 Sep 4;95(5):581-6. Epub 2006 Aug 1. [PubMed:16880785 ]
  5. Lu X, Tang X, Guo W, Ren T, Zhao H: Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway. J Surg Oncol. 2010 Dec 1;102(7):821-6. doi: 10.1002/jso.21661. [PubMed:20812347 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Protein serine/threonine kinase activity
Specific Function:
Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that com...
Gene Name:
RAF1
Uniprot ID:
P04049
Molecular Weight:
73051.025 Da
References
  1. Adnane L, Trail PA, Taylor I, Wilhelm SM: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597-612. [PubMed:16757355 ]
  2. Gollob JA, Wilhelm S, Carter C, Kelley SL: Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol. 2006 Aug;33(4):392-406. [PubMed:16890795 ]
  3. Huether A, Hopfner M, Baradari V, Schuppan D, Scherubl H: Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol. 2007 May 1;73(9):1308-17. Epub 2007 Jan 5. [PubMed:17266941 ]
  4. Cascone T, Gridelli C, Ciardiello F: Combined targeted therapies in non-small cell lung cancer: a winner strategy? Curr Opin Oncol. 2007 Mar;19(2):98-102. [PubMed:17272980 ]
  5. Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A: Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist. 2007 Feb;12(2):191-200. [PubMed:17296815 ]
  6. Lu X, Tang X, Guo W, Ren T, Zhao H: Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway. J Surg Oncol. 2010 Dec 1;102(7):821-6. doi: 10.1002/jso.21661. [PubMed:20812347 ]
  7. Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y, Nathanson KL, Herlyn M: CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene. 2009 Jan 8;28(1):85-94. doi: 10.1038/onc.2008.362. Epub 2008 Sep 15. [PubMed:18794803 ]
  8. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008 Oct;7(10):3129-40. doi: 10.1158/1535-7163.MCT-08-0013. [PubMed:18852116 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced pr...
Gene Name:
FLT4
Uniprot ID:
P35916
Molecular Weight:
152755.94 Da
References
  1. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P: Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 2006 May;57(5):685-92. Epub 2005 Aug 25. [PubMed:16133532 ]
  2. Adnane L, Trail PA, Taylor I, Wilhelm SM: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597-612. [PubMed:16757355 ]
  3. Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A: Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist. 2007 Feb;12(2):191-200. [PubMed:17296815 ]
  4. Strumberg D: Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc). 2005 Dec;41(12):773-84. [PubMed:16474853 ]
  5. Reddy GK, Bukowski RM: Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma. Clin Genitourin Cancer. 2006 Mar;4(4):246-8. [PubMed:16729906 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domai...
Gene Name:
KDR
Uniprot ID:
P35968
Molecular Weight:
151525.555 Da
References
  1. Schoffski P, Dumez H, Clement P, Hoeben A, Prenen H, Wolter P, Joniau S, Roskams T, Van Poppel H: Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol. 2006 Aug;17(8):1185-96. Epub 2006 Jan 17. [PubMed:16418310 ]
  2. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O'Dwyer PJ: Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006 Mar 20;24(9):1363-9. Epub 2006 Jan 30. [PubMed:16446323 ]
  3. Rini BI: Sorafenib. Expert Opin Pharmacother. 2006 Mar;7(4):453-61. [PubMed:16503817 ]
  4. Adnane L, Trail PA, Taylor I, Wilhelm SM: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597-612. [PubMed:16757355 ]
  5. Lacouture ME, Desai A, Soltani K, Petronic-Rosic V, Laumann AE, Ratain MJ, Stadler WM: Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol. 2006 Nov;31(6):783-5. Epub 2006 Jul 4. [PubMed:16824050 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or...
Gene Name:
FLT3
Uniprot ID:
P36888
Molecular Weight:
112902.51 Da
References
  1. Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, Zhang X, Wilkie D, Burd A, Shi H, Rocks S, Gedrich R, Abriola L, Vasavada H, Lynch M, Dumas J, Trail PA, Wilhelm SM: Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia. 2007 Mar;21(3):439-45. Epub 2007 Jan 4. [PubMed:17205056 ]
  2. Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, Cools J: The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica. 2007 Jan;92(1):27-34. [PubMed:17229632 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Vascular endothelial growth factor binding
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of peri...
Gene Name:
PDGFRB
Uniprot ID:
P09619
Molecular Weight:
123966.895 Da
References
  1. Gollob JA: Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Clin Genitourin Cancer. 2005 Dec;4(3):167-74. [PubMed:16425993 ]
  2. Guida T, Anaganti S, Provitera L, Gedrich R, Sullivan E, Wilhelm SM, Santoro M, Carlomagno F: Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13(11):3363-9. [PubMed:17545544 ]
  3. Unnithan J, Rini BI: The role of targeted therapy in metastatic renal cell carcinoma. ScientificWorldJournal. 2007 Mar 2;7:800-7. [PubMed:17619763 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1...
Gene Name:
KIT
Uniprot ID:
P10721
Molecular Weight:
109863.655 Da
References
  1. Guida T, Anaganti S, Provitera L, Gedrich R, Sullivan E, Wilhelm SM, Santoro M, Carlomagno F: Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13(11):3363-9. [PubMed:17545544 ]
  2. Koch CA, Gimm O, Vortmeyer AO, Al-Ali HK, Lamesch P, Ott R, Kluge R, Bierbach U, Tannapfel A: Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy? Ann N Y Acad Sci. 2006 Aug;1073:517-26. [PubMed:17102120 ]
  3. Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, Cools J: The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica. 2007 Jan;92(1):27-34. [PubMed:17229632 ]
  4. Cascone T, Gridelli C, Ciardiello F: Combined targeted therapies in non-small cell lung cancer: a winner strategy? Curr Opin Oncol. 2007 Mar;19(2):98-102. [PubMed:17272980 ]
  5. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006 Dec 15;66(24):11851-8. [PubMed:17178882 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (...
Gene Name:
FGFR1
Uniprot ID:
P11362
Molecular Weight:
91866.935 Da
References
  1. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109. [PubMed:15466206 ]
  2. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M: BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006 Mar 1;98(5):326-34. [PubMed:16507829 ]
  3. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006 Oct;5(10):835-44. [PubMed:17016424 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during in...
Gene Name:
RET
Uniprot ID:
P07949
Molecular Weight:
124317.465 Da
References
  1. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109. [PubMed:15466206 ]
  2. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M: BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006 Mar 1;98(5):326-34. [PubMed:16507829 ]
  3. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006 Oct;5(10):835-44. [PubMed:17016424 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Vegf-b-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation ...
Gene Name:
FLT1
Uniprot ID:
P17948
Molecular Weight:
150767.185 Da
References
  1. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109. [PubMed:15466206 ]
  2. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M: BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006 Mar 1;98(5):326-34. [PubMed:16507829 ]
  3. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006 Oct;5(10):835-44. [PubMed:17016424 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Gomo C, Coriat R, Faivre L, Mir O, Ropert S, Billemont B, Dauphin A, Tod M, Goldwasser F, Blanchet B: Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4. doi: 10.1007/s10637-010-9514-3. Epub 2010 Aug 13. [PubMed:20706860 ]
  2. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  3. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ: Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8. doi: 10.1007/s00280-011-1585-0. Epub 2011 Feb 25. [PubMed:21350850 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ: Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8. doi: 10.1007/s00280-011-1585-0. Epub 2011 Feb 25. [PubMed:21350850 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ: Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8. doi: 10.1007/s00280-011-1585-0. Epub 2011 Feb 25. [PubMed:21350850 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ: Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8. doi: 10.1007/s00280-011-1585-0. Epub 2011 Feb 25. [PubMed:21350850 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ: Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8. doi: 10.1007/s00280-011-1585-0. Epub 2011 Feb 25. [PubMed:21350850 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ: Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8. doi: 10.1007/s00280-011-1585-0. Epub 2011 Feb 25. [PubMed:21350850 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ: Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8. doi: 10.1007/s00280-011-1585-0. Epub 2011 Feb 25. [PubMed:21350850 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Gomo C, Coriat R, Faivre L, Mir O, Ropert S, Billemont B, Dauphin A, Tod M, Goldwasser F, Blanchet B: Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4. doi: 10.1007/s10637-010-9514-3. Epub 2010 Aug 13. [PubMed:20706860 ]
  2. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  3. Keating GM, Santoro A: Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69(2):223-40. doi: 10.2165/00003495-200969020-00006. [PubMed:19228077 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. doi: 10.1158/1078-0432.CCR-09-0048. Epub 2009 Sep 22. [PubMed:19773380 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. doi: 10.1158/1078-0432.CCR-09-0048. Epub 2009 Sep 22. [PubMed:19773380 ]
  2. Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH: Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010 Feb;9(2):319-26. doi: 10.1158/1535-7163.MCT-09-0663. Epub 2010 Jan 26. [PubMed:20103600 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. doi: 10.1158/1078-0432.CCR-09-0048. Epub 2009 Sep 22. [PubMed:19773380 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. doi: 10.1158/1078-0432.CCR-09-0048. Epub 2009 Sep 22. [PubMed:19773380 ]
  2. Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH: Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010 Feb;9(2):319-26. doi: 10.1158/1535-7163.MCT-09-0663. Epub 2010 Jan 26. [PubMed:20103600 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transmembrane transporter activity
Specific Function:
Can activate specifically hydrolysis of GTP bound to RAC1 and CDC42, but not RALA. Mediates ATP-dependent transport of S-(2,4-dinitrophenyl)-glutathione (DNP-SG) and doxorubicin (DOX) and is the major ATP-dependent transporter of glutathione conjugates of electrophiles (GS-E) and DOX in erythrocytes. Can catalyze transport of glutathione conjugates and xenobiotics, and may contribute to the mul...
Gene Name:
RALBP1
Uniprot ID:
Q15311
Molecular Weight:
76062.86 Da
References
  1. Singhal SS, Sehrawat A, Sahu M, Singhal P, Vatsyayan R, Rao Lelsani PC, Yadav S, Awasthi S: Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38. doi: 10.1002/ijc.24767. [PubMed:19626587 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 02:14